Search Blog
Categories
October 2018
M T W T F S S
« Sep   Nov »
1234567
891011121314
15161718192021
22232425262728
293031  

Tags

NexgenRx Announces Completion of $425,000 Equity Financing

FSCWIRE

NexgenRx Announces Completion of $425,000 Equity Financing

Toronto, Ontario (FSCwire)NEXGENRX INC. (“NexgenRx” or the “Corporation”) announces the completion of a private placement financing, pursuant to which it has issued an aggregate of 1,700,000 common shares of the Corporation (each, a “Common Share”) at a price of $0.25 per Common Share for aggregate gross proceeds of $425,000. The proceeds of this offering will be used to fund future technology, product and software development, as well as to provide general working capital for 2018. Four-month hold periods apply to the securities issued under this offering (expiring February 12, 2019) in accordance with applicable securities laws. Four insiders participated in the offering, acquiring an aggregate of 400,000 Common Shares. The foregoing subscriptions are considered to be related party transactions and are therefore subject to the provisions of Multilateral Instrument 61-101 – “Protection of Minority Security Holders in Special Transactions“, however exemptions are available from the minority shareholder approval and valuation requirements set forth in the foregoing Multilateral Instrument.

About NexgenRx

NexgenRx is Canada’s only independent full service technology solutions provider, offering proprietary full front end enrolment, hour bank and mobile access capabilities, combined with state of the art claims adjudication and full provider network coverage. These combined capabilities allow NexgenRx to provide complete proprietary solutions to plan sponsors that need sophisticated front end administration and health benefit technology applications, all in a cost- effective manner. NexgenRx is committed to building partnerships with organizations looking to exceed the expectations of their clients and plan members and deliver superior administration and claims processing solutions at a competitive cost. More information on NexgenRx can be found at www.nexgenrx.com.

Caution Regarding Forward-Looking Statements

Except for statements of historical fact, this news release contains certain “forward-looking information” within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as “plan”, “expect”, “project”, “intend”, “believe”, “anticipate”, “estimate” and other similar words, or statements that certain events or conditions “may” or “will” occur. In particular, forward-looking information in this press release includes, but is not limited to references to the use of proceeds of this offering. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance or achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for existing and new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; continued development and enhancement of the Company’s proprietary software technology; cyber security risks and the other risks and uncertainties disclosed in our annual Management’s Discussion and Analysis, as filed under our profile on SEDAR at www.sedar.com. Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of the release.

FOR FURTHER INFORMATION PLEASE CONTACT:

Ronald C. Loucks

Kelly Ehler CPA, CA

NexgenRx Inc.

NexgenRx Inc.

President and CEO

Chief Financial Officer

416.695.3393 x801

416-695-3393×803

To view the original release, please click

Maximum News Dissemination by FSCwire. https://www.fscwire.com

Copyright © 2018 FSCwire